Supplemental Financial Information Third Quarter Ended September 30, 2020 November 4, 2020 Exhibit 99.2

Forward-Looking Statements This presentation contains “forward-looking statements” (as defined in the Securities Litigation Reform Act of 1995) regarding, among other things, future events or the future financial performance of the Company.  Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” “will,” “estimate,” “may,” “could,” “should,” “outlook,” and “guidance” and words and terms of similar substance used in connection with any discussion of future plans, actions, events or results identify forward-looking statements.   Forward-looking statements are based on information currently available to the Company and involve estimates, expectations and projections. Investors are cautioned that all such forward-looking statements are subject to risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including, but not limited to, the risks and uncertainties related to the COVID-19 pandemic and those otherwise described in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Many of these risks, uncertainties and assumptions are beyond the Company’s ability to control or predict. Because of these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Non-GAAP Financial Information   This presentation includes certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including EBITDA and Adjusted EBITDA. The company uses these non-GAAP financial measures in operating its business because management believes they are less susceptible to variances in actual operating performance that can result from the excluded items. The company presents these financial measures to investors because they believe they are useful to investors in evaluating the primary factors that drive the company's operating performance. The items excluded from these non-GAAP measures are important in understanding LHC Group’s financial performance, and any non-GAAP measures presented should not be considered in isolation of, or as an alternative to, GAAP financial measures. Since these non-GAAP financial measures are not measures determined in accordance with GAAP, have no standardized meaning prescribed by GAAP and are susceptible to varying calculations, these measures, as presented, may not be comparable to other similarly titled measures of other companies.  EBITDA of LHC Group is defined as net income (loss) before income tax benefit (expense), interest expense, and depreciation and amortization expense. Adjusted EBITDA of LHC Group is defined as net income (loss) before income tax expense benefit (expense), depreciation and amortization expense, and transaction costs related to previous transactions. Please visit the Investors section on our website at Investor.LHCgroup.com for additional information on LHC Group and the industry. Nasdaq: LHCG

Table of Contents Company overview Commentary on Q3 2020 COVID-19 update Consolidated results Adjustments to net income Medicare Shared Savings Program Q3 impact Segment results Guidance Acquisitions and joint ventures Quality data Debt and liquidity metrics Focus for remainder of 2020 31-32 Non-GAAP reconciliations 30 29 28 27 26 18-25 17 15-16 13-14 6-12 5 4

Home Health Hospice HCBS Home Health & Hospice Home Health & HCBS Home Health, Hospice, & HCBS LHC Group Overview 549 home health locations 60% Of U.S. population aged 65+ included in service area 111 hospice locations 122 home & community based services locations 12 Long term acute care hospitals locations 29 other service locations 823 total locations 400 leading hospital JV partners 35 states and District of Columbia

After experiencing maximum year-to-date headwinds from COVID-19 in mid-April, organic growth, average daily census and admissions in home health and hospice steadily increased through Q3. Home Health average daily census is currently 12.4% higher than COVID induced low point and 7.1% higher than pre COVID levels. Net service revenue increased 0.4% for Q3 as compared to Q3 2019. While we are pleased to have positive revenue growth during the pandemic, our revenue growth was negatively effected by COVID-19. Adjusted net income attributable to LHC Group’s common stockholders increased 29.8% to $51.3 million, or $1.63 adjusted earnings per diluted share, as compared to Q3 2019. Adjusted EBITDA increased 25.0% to $74.5 million, as compared to Q3 2019. Our confidence remains high in our PDGM execution as we continue to improve on our revenue per episode sequentially and are benefiting from the execution of cost initiatives that were one to two quarters ahead of schedule. Organic growth in admissions for home health locations increased 4.7% for the quarter compared to the same period in 2019 with 13.1% same store sequential growth over the second quarter of 2020. Our non-Medicare episodic same store admissions have grown 34.0% year over year. The majority of this growth is from episodic contracts that pay Medicare rates. Organic growth in admissions for hospice increased 12.8% for the quarter compared to the same period in 2019 with 8.3% same store sequential growth over the second quarter of 2020. Momentum from new physician referral sources continues with nearly 4,600 new home health referral sources added in the third quarter alone. Based on continued improvement in sequential trends and success of operating within new PDGM care models and current reality of the COVID-19 environment, we increased our guidance of net service revenue to $2.06 billion to $2.07 billion ($2.0 billion to $2.05 billion previously), adjusted earnings per diluted share to $4.90 to $5.00 ($4.60 to $4.80 previously) and Adjusted EBITDA of $232 million to $237 million ($220 million to $230 million previously). Commentary on Q3 2020

Multi-disciplinary internal COVID-19 task force continues to meet weekly and send company wide COVID-19 related communications daily. Every employee is screened daily based on CDC guidelines, and every patient (regardless of condition) is seen by a clinician with at least face mask and gloves while COVID patients (confirmed or suspect) are seen by a clinician with full PPE. Since onset of the pandemic, LHC Group has treated nearly 11,567 active patients either COVID confirmed or suspected. LHC Group has invested in the sourcing of PPE, directly and through normal channels, and has ensured adequate par levels of PPE for future use. We have also developed and implemented a more efficient warehousing system and improved our shipping process with more strategic storage locations to ensure timely distribution and receipt of PPE at all locations. We conduct daily online screenings of every employee, perform temperature checks when entering offices and agencies, practice social distancing and wear masks in common areas, enact contact tracing when suspected exposures occur, maintain 25-50% office occupancy according to state mandates, and have thorough office cleaning and disinfecting protocols. Introduced programs to support employees, including a pandemic grant program under our 501(c)(3) LHC Group Purpose Fund, retirement plan amendments, special cash-in opportunities for accumulated paid time off, expanded offerings in our employee assistance program, a wage supplement program for front line direct patient care-giving employees, and a one-time make whole PTO replenishment program for front line direct patient care-giving employees and for any employees who previously donated their PTO hours to them. Implemented cost containment initiatives such as eliminating non-essential travel and expenses and other measures. Liquidity remains strong with no net debt and approximately $500 million from cash and availability on the revolving credit facility. The pandemic has reinforced the preferred setting of care in the home among referring physicians, hospitals, families and patients with an expectation that these stakeholders will increasingly divert admissions from SNFs and other congregate settings to home. COVID-19 Update: General

COVID-19 Update: Home Health and Hospice Growth Trends Same Store Organic Admission Growth by 2020 Period over Same Period in 2019 Jan 2020 Feb 2020 Mar 2020 Q1 2020 Home Health 9.8% 13.4% -1.6% 7.1% Hospice 1.5% 2.5% -3.1% 0.2% Apr 2020 May 2020 Jun 2020 Q2 2020 Home Health -14.3% -6.7% 7.0% -4.7% Hospice -7.2% 2.7% 10.4% 1.8% Jul 2020 Aug 2020 Sept 2020 Q3 2020 Home Health 9.2% 0.0% 5.2% 4.7% Hospice 9.9% 13.3% 15.1% 12.8% Same Store Organic Sequential Growth Q1 2020 vs Q4 2019 Q2 2020 vs Q1 2020 Q3 2020 vs Q2 2020 Home Health 7.4% -11.5% 13.1% Hospice 16.8% 0.6% 8.3%

COVID-19 Update: New Physician Home Health Referral Sources 2019 2020 Growth January 1,392 1,474  5.9% February 1,161 1,282 10.4% March 1,241 1,159 -6.6% April 1,184 1,205 1.8% May 1,169 1,294 10.7% June 1,091 1,497 37.2% July 1,078 1,512 40.3% August 1,150 1,553 35.0% September 1,003 1,517 51.2% September year-to-date 10,469 12,493 19.3%

State % of total HH volume Q2 2020 Q3 2020 Florida 9.0% 5.4% 14.0% Tennessee 8.8% -2.6% 2.3% Kentucky 7.7% -5.0% -1.8% Alabama 7.5% -7.3% 0.5% Mississippi 6.6% -3.2% 0.8% Louisiana 6.3% 6.7% 12.1% Arkansas 6.3% -14.0% 0.8% Pennsylvania 5.6% -16.2% -5.8% Texas 4.8% 7.2% 22.5% West Virginia 4.1% -5.5% 0.8% Georgia 3.3% 3.2% 13.4% New Jersey 3.1% -7.1% 14.2% Ohio 3.0% 3.0% 29.4% Illinois 2.7% -17.1% -0.1% Massachusetts 2.5% -6.3% 19.0% Total % of volume 81.3% COVID-19 Update: Home Health Same Store Organic Admission Growth by 2020 Period over Same Period in 2019 Top 15 States by Admission Volume in the Third Quarter of 2020

COVID-19 Update: Pre COVID-19 Trends Compared with Current Trends continued Monthly Home Health, Hospice and HCBS Trends                                 Week Ending January 2020 February 2020 March 2020 April 2020 May 2020 June 2020 July 2020 August 2020 September 2020 October 2020 Home Health:                     Average census 75,027 77,391 78,515 74,817 76,791 80,983 81,775 82,184 82,805 84,091 Admissions 38,083 36,240 33,859 27,948 31,069 34,465 35,180 34,706 34,418 36,786  Admission of COVID-19 positive patients - - 193 1,113 1,438 679 1,319 1,462 842 1,403  Patient declined admission due to COVID-19 concern - - 925 558 298 182 179 165 115 103  Missed visits due to COVID-19 - - 14,995 22,913 4,524 830 1,411 1,175 569 722  LUPA % on PDGM episodes n/a  n/a  8.8% 11.4% 8.8% 8.2% 8.6% 8.6% 8.9% 7.9% Virtual visits and Telehealth 34,040 58,241 83,802 98,565 83,741 78,978 77,906 75,403 72,249 63,234 Institutional vs Community admission 63.5% 65.0% 67.3% 58.1% 57.8% 59.4% 60.9% 59.8% 60.8% 63.0%   Hospice: Admissions 1,779 1,625 1,656 1,544 1,640 1,685 1,650 1,709 1,718 1,853  Admission of COVID-19 positive patients - 1 2 36 51 34 68 110 46 41  Average census 4,393 4,433 4,450 4,469 4,524 4,616 4,597 4,615 4,518 4,509   HCBS: HCBS billable hours 691,592 629,139 664,868 631,966 638,009 651,926 666,291 638,406 638,009 640,668  HCBS billable hours missed due to COVID-19 - 24 9,735 53,906 52,817 25,707 21,185 20,239 12,865 12,480 

COVID-19 Update: Financial Impact of CARES Act Policies Near-term financial benefits are substantial Estimated 2020 financial impact Provider Relief Fund As of September 30, 2020, we have received funds totaling $93.3 million related to the Provider Relief Fund as provided for by the CARES Act. During the three months ended June 30, 2020, we recognized $44.4 million ($27.2 million net of non-controlling interest and tax),or $0.87 per diluted share, in government stimulus income related to general distribution funds received from the Provider Relief Fund. During the three months ended September 30, 2020, we reversed $44.4 million such that we recognized no funds for the nine months ended September 30, 2020. The full amount received, $93.3 million, was recorded as a short-term liability in government stimulus advance in our condensed consolidated balance sheet. It is our intent to return the funds to the government. Advanced Accelerated Payment Since April 2020, we received funds totaling $317.9 million under the Medicare Accelerated and Advance Payment Program as provided for by the CARES Act. The accelerated Medicare payments are interest free and the program currently requires that the Centers for Medicare and Medicaid Services (“CMS”) recoup the accelerated payments beginning 12 months after receipt by the provider by withholding 25% of future Medicare fee-for service payments for claims for eleven months and then withholding 50% of future Medicare fee-for service payments for claims for an additional six months. An interest rate of 4% will be assessed on any outstanding balances after 29 months from the date of the initial advance. Cash flows from operations for the nine months ended 2020 included $317.9 million of accelerated Medicare payments, all of which remains deferred on the balance sheet at September 30, 2020. Payroll Tax Deferral The CARES Act permits employers to defer the deposit and payment of the employer's portion of social security taxes that otherwise would be due between March 27, 2020, and December 31, 2020. The law permits employers instead to deposit half of these deferred payments by the end of 2021 and the other half by the end of 2022. For the nine months ended September 30, 2020, the cash benefit for LHC Group was $33.6 million and we estimate the cash benefit to be $50 million to $55 million in 2020. Sequestration Holiday The CARES Act temporarily suspends Medicare sequestration for the period of May 1 through December 31, 2020. As a result, health care providers can expect to receive an increase in fee-for-service Medicare payments by approximately 2%. The suspension of sequestration provided $11.5 million in additional Medicare revenue during the nine months ended September 30, 2020 and we estimate the total amount to be an approximately $15 million to $20 million positive impact to revenue for the period of May 1 through December 31, 2020.

COVID-19 Update: CARES Act Policy Implications Potential benefits that could lead to new homecare policies post-COVID-19 Policy Benefit Nurse Practioners and Physician Assistants are permanently authorized to order and certify home health services. Nurse Practitioners and Physician Assistants can order and follow a home health plan of care and conduct face-to-face visits. HHS is directed to encourage the use of telehealth, including remote patient monitoring in the home. While not yet a separately reimbursed benefit, it’s a step in the right direction and gives us increased flexibilities for technology in the home. The introduction of the HEAT Act, bipartisan legislation recently introduced in both the House and Senate to reimburse home health agencies for the use of telehealth, could have a material financial benefit and potentially reimburse us for our costs in providing this vital service. Nurse Practitioners and Physician Assistants are permitted to conduct face to face recertification for hospice eligibility via telehealth. Creates greater regulatory flexibilities and greater benefit to our patients in the home.

2020 Adjusted Consolidated Results   Three months ended September 30 Nine months ended September 30 Consolidated Total Adjustments Adjusted Consolidated Consolidated Total Adjustments Adjusted Consolidated Net service revenue $530,684 $0 $530,684 $1,530,875 $0 $1,530,875 Cost of service revenue 305,246 (5,220) 300,026 933,160 (26,775) 906,385 Gross margin 225,438   230,658 597,715   624,490 General and administrative expenses 161,463 (7,724) 153,739 469,903 (18,942) 450,961 Government stimulus income (44,435) 44,435 0 0 0 0 Impairment of intangibles and other 22 (22) 0 622 (622) 0 Operating income (loss) $19,518 $57,401 $76,919 $127,190 $46,339 $173,529 Depreciation 5,217 0 5,217 15,601 0 15,601 Noncontrolling interests 8 (7,626) (7,618) (18,753) 0 (18,753) Earnings before interest, tax and depreciation (EBITDA less NCI) $24,743 $49,775 $74,518 $124,038 $46,339 $170,377 EBITDA less NCI as a percentage of revenue 4.7%   14.0% 8.1%   11.1%

Adjusted Consolidated Results – 2020 vs 2019 Three months ended September 30 Nine months ended September 30 2020 Adjusted Consolidated % of rev 2019 Adjusted Consolidated % of rev 2020 Adjusted Consolidated % of rev 2019 Adjusted Consolidated % of rev Net service revenue $530,684   $528,499   $1,530,875   $1,548,926   Cost of service revenue 300,026 56.5% 331,433 62.7% 906,385 59.2% 970,675 62.7% Gross margin 230,658 43.5% 197,066 37.3% 624,490 40.8% 578,251 37.3% General and administrative expenses 153,739 29.0% 137,328 26.0% 450,961 29.5% 418,272 27.0% Operating income $76,919 14.5% $59,738 11.3% $173,529 11.3% $159,979 10.3% Depreciation 5,217   4,412   15,601   12,812   Noncontrolling interests (7,618)   (4,534)   (18,753)   (14,017)   Earnings before interest, tax and depreciation (EBITDA less NCI) $74,518   $59,616   $170,377   $158,774   EBITDA less NCI as a percentage of revenue 14.0%   11.3%   11.1%   10.3%  

Adjustments to Net Income PRE-TAX ADJUSTMENTS Q3 2020 Q3 2019 YTD 2020 YTD 2019 Acquisition and de novo expenses (1) $2,492 $11,731 $4,556 $28,305 Closures/relocations/consolidations (2) $0 $1,302 $1,174 $6,536 COVID-19 PPE, supplies and other expenses (3) $10,474 $0 $40,609 $0 Provider Relief Fund (PRF) (5) $44,435 $0 $0 $0 NCI associated with PRF (6) $(7,626) $0 $0 $0 Provider moratorium impairment (7) $0 $0 $0 $6,000 Total $49,775 $13,033 $46,339 $40,841 ADJUSTMENTS NET OF TAX Q3 2020 Q3 2019 YTD 2020 YTD 2019 Acquisition and de novo expenses (1) $1,829 $8,482 $3,345 $20,463 Closures/relocations/consolidations (2) $0 $941 $866 $4,722 COVID-19 impact: PPE, supplies and other expenses (3) $7,689 $0 $29,967 $0 CARES Act tax benefit (4) $0 $0 $(2,210) $0 Provider Relief Fund (PRF) (5) $32,882 $0 $0 $0 NCI associated with PRF (6) $(5,643) $0 $0 $0 Provider moratorium impairment (7) $0 $0 $0 $4,332 Total $36,757 $9,423 $31,968 $29,517 *See footnotes on page 16

Adjustments to Net Income per Diluted Share ADJUSTMENTS NET OF TAX Q3 2020 Q3 2019 YTD 2020 YTD 2019 Acquisition and de novo expenses (1) $0.05 $0.27 $0.11 $0.66 Closures/relocations/consolidations (2) $0 $0.03 $0.03 $0.15 COVID-19 impact: PPE, supplies and other expenses (3) $0.25 $0 $0.95 $0 CARES Act tax benefit (4) $0 $0 $(0.07) $0 Provider Relief Fund (PRF) (5) $1.05 $0 0 $0 NCI associated with PRF (6) $(0.18) $0 $0 $0 Provider moratorium impairment (7) $0 $0 $0 $0.14 Total $1.17 $0.30 $1.02 $0.95 Footnotes: Expenses and other costs associated with recently announced or completed acquisitions and de novos ($2.5 million and $4.6 million pre-tax in the third quarter and first nine months of 2020, respectively). Loss on the sale of an asset and other expenses associated with a closure on consolidation (none in the third quarter and $1.2 million pre-tax in the first nine months of 2020). COVID-19 related expenses for purchases of personal protective equipment (PPE), supplies and employee benefit expenses including bonuses and increased wages, wage supplements and PTO replenishments for front line caregivers ($10.5 million and $40.6 million pre-tax in the third quarter and first nine months of 2020, respectively). Tax benefit related to new legislation in the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which lifts certain tax deduction limitations and eliminates 80% of taxable income limitations for Net Operating Losses (“NOL”), which we are now able to fully utilize NOLs associated with Almost Family prior to the merger. Based on improved current and projected future results, the Company intends to return the entire $93.3 million in funds it has received from the Provider Relief Fund (PRF) under the CARES Act and for the consolidated results for the third quarter of 2020 has reversed the $44.4 million in government stimulus income recognized during the second of 2020 related to general distribution funds received from the PRF ($44.4 million pre-tax). Non-controlling interest distributed to our Joint Venture partners in association with the government stimulus income recognized during the second quarter of 2020 ($7.6 million pre-tax) was reversed in the three months ended September 30, 2020 based on the reversal of the government stimulus income recognized during the second quarter of 2020. During the first quarter of 2019, the Company recorded $6.0 million of moratoria impairment as a result of the Centers for Medicare and Medicaid Services (“CMS”) action to remove all federal moratoria with regard to Medicare provider enrollment. In assigning fair value acquired in acquisitions as required by ASC 805, Business Combinations, the Company had assigned fair value to Certificates of need or license moratoria, as applicable, in certain states.

Medicare Shared Savings Program Q3 Impact Adjusted Q3 (Includes $9.6 million in MSSP*) Q3 with budgeted MSSP (Includes $5.0 million in MSSP*) Normalized Q3 (Excluding MSSP*) Revenue $530.7 million $526.1 million $521.1 million EPS $1.63 $1.52 $1.40 EBITDA $74.5 million $70.0 million $65.0 million The Healthcare Innovations (“HCI”) segment provides strategic health management services to Accountable Care Organizations ("ACOs") that have been approved to participate in the Medicare Shared Savings Program ("MSSP"). The HCI segment has service agreements with ACOs that provide for sharing of MSSP payments received by the ACO, if any. The MSSP payment is calculated in the third quarter of each year. The MSSP is an alternative payment model in which eligible providers, hospitals, and suppliers are rewarded for achieving better health for individuals, improving population health, and lowering growth in healthcare expenditures. Our HCI segment received $9.6 million in payments from CMS and the Medicare Shared Savings Program in the third quarter of 2020 as compared to a budget of $5 million. *

Three Months Ended Sep. 30, 2020 Adjusted Segment Results Home health services Adjustments Adjusted Home health services   Hospice services Adjustments Adjusted Hospice services   HCBS services Adjustments Adjusted HCBS services Net service revenue $373,450   $373,450   $59,801   $59,801   $48,387   $48,387 Cost of service revenue 205,523 (4,324) 201,199   37,180 (534) 36,646   36,664 (17) 36,647 Gross margin 167,927   172,251   22,621   23,155   11,723   11,740 General and administrative expenses 118,792 (5,552) 113,240   16,668 (801) 15,867   10,937 (858) 10,079 Government stimulus income (35,019) 35,019 0 (4,731) 4,731 0 (2,865) 2,865 0 Impairment of intangibles and other 22 (22) 0 0 0 0 0 0 0 Operating income (loss) $14,094 $44,917 $59,011   $1,222 $6,066 $7,288   ($2,079) $3,740 $1,661 Add back Depreciation 3,043   3,043   509   509   418   418 Less Noncontrolling interests 157 (6,226) (6,069)   (321) (980) (1,301)   153 (178) (25) Earnings before interest, tax and depreciation (EBITDA less NCI) $17,294 $38,691 $55,985   $1,410 $5,086 $6,496   ($1,508) $3,562 $2,054 EBITDA less NCI as a percentage of revenue 4.6%   15.0%   2.4%   10.9%   -3.1%   4.2% Facility-based services Adjustments Adjusted Facility-based services   HCI Adjustments Adjusted HCI services Net service revenue $33,344   $33,344   $15,702   $15,702 Cost of service revenue 22,213 (345) 21,868   3,666   3,666 Gross margin 11,131   11,476   12,036   12,036 General and administrative expenses 11,439 (459) 10,980   3,627 (54) 3,573 Government stimulus income (1,656) 1,656 0 (164) 164 0 Impairment of intangibles and other 0 0 0 0 0 0 Operating income (loss) ($1,964) $2,460 $496   $8,245 $218 $8,463 Add back Depreciation 945   945   302   302 Less Noncontrolling interests 12 (242) (230)   7 0 7 Earnings before interest, tax and depreciation (EBITDA less NCI) ($1,007) $2,218 $1,211   $8,554 $218 $8,772 EBITDA less NCI as a percentage of revenue -3.0%   3.6%   54.5%   55.9%

Nine Months Ended Sep. 30, 2020 Adjusted Segment Results Home health services Adjustments Adjusted Home health services   Hospice services Adjustments Adjusted Hospice services   HCBS services Adjustments Adjusted HCBS services Net service revenue $1,081,143 $0 $1,081,143   $181,387 $0 $181,387   $144,526 $0 $144,526 Cost of service revenue $631,109 ($20,258) 610,851   $112,485 ($2,562) 109,923   $113,864 ($2,378) 111,486 Gross margin 450,034   470,292   68,902   71,464   30,662   33,040 General and administrative expenses 345,024 (13,312) 331,712   49,560 (2,142) 47,418   33,520 (1,898) 31,622 Government stimulus income 0 0 0 0 0 0 0 0 0 Impairment of intangibles and other 22 (22) 0 600 (600) 0 0 0 0 Operating income (loss) $104,988 $33,592 $138,580   $18,742 $5,304 $24,046   ($2,858) $4,276 $1,418 Depreciation 9,132   9,132   1,545   1,545   1,217   1,217 Noncontrolling interests (14,371) 0 (14,371)   (3,452) 0 (3,452)   275 0 275 Earnings before interest, tax and depreciation (EBITDA less NCI) $99,749 $33,592 $133,341   $16,835 $5,304 $22,139   ($1,366) $4,276 $2,910 EBITDA less NCI as a percentage of revenue 9.2%   12.3%   9.3%   12.2%   -0.9%   2.0% Facility-based services Adjustments Adjusted Facility-based services   HCI Adjustments Adjusted HCI services Net service revenue $96,664 $0 $96,664   $27,155 $0 $27,155 Cost of service revenue $64,340 ($1,487) 62,853   $11,362 ($90) 11,272 Gross margin 32,324   33,811   15,793   15,883 General and administrative expenses 31,984 (1,458) 30,526   9,815 (132) 9,683 Government stimulus income 0 0 0 0 0 0 Impairment of intangibles and other 0 0 0 0 0 0 Operating income (loss) $340 $2,945 $3,285   $5,978 $222 $6,200 Depreciation 2,810   2,810   897   897 Noncontrolling interests (1,228) 0 (1,228)   23 0 23 Earnings before interest, tax and depreciation (EBITDA less NCI) $1,922 $2,945 $4,867   $6,898 $222 $7,120 EBITDA less NCI as a percentage of revenue 2.0%   5.0%   25.4%   26.2%

Three months ended September 30, Nine months ended September 30, 2020 Adjusted Home health services % of rev 2019 Adjusted Home health services % of rev   2020 Adjusted Home health services % of rev 2019 Adjusted Home health services % of rev Net service revenue $373,450   $375,599     $1,081,143   $1,113,887   Cost of service revenue 201,199 53.9% 234,729 62.5%   610,851 56.5% 685,190 61.5% Gross margin 172,251 46.1% 140,870 37.5%   470,292 43.5% 428,697 38.5% General and administrative expenses 113,240 30.3% 99,043 26.4%   331,712 30.7% 303,185 27.2% Operating income $59,011 15.8% $41,827 11.1% $138,580 12.8% $125,512 11.3% Depreciation 3,043   2,557   9,132   7,369   Noncontrolling interests (6,069)   (3,577)     (14,371)   (11,305)   Earnings before interest, tax and depreciation (EBITDA less NCI) $55,985   $40,807     $133,341   $121,576   EBITDA less NCI as a percentage of revenue 15.0%   10.9%     12.3%   10.9%   Home Health Adjusted EBITDA margin improved 410 basis points in the third quarter of 2020 compared to the same period in 2019. Gross margin improved 860 basis points due to cost initiatives related to PDGM and a reduction in visits and transportation caused by the COVID-19 pandemic but was offset by an increase of 390 basis points in general and administrative expense as a percent of revenue in the third quarter of 2020 as compared to the same period in 2019. The increase in G&A as a percent of revenue is due to lower home health revenue per episode due to a decrease in patient acuity caused by the COVID-19 pandemic and an increase in G&A expense due to cost associated with an investment in our technology infrastructure of approximately $4 million in the third quarter. Home Health Adjusted EBITDA margin improved 200 basis points sequentially from 13.0% in the second quarter of 2020 to 15.0% in the third quarter of 2020. Revenue from sequestration suspension in the third quarter of 2020 was $5.1 million. Home Health Segment Adjusted Segment Results – 2020 vs 2019

% of P2s out of total 30-day periods Institutional admit % LUPA % 60-day case mix March 2020 42.8% 67.3% 8.8% 1.0260 April 2020 43.1% 58.1% 11.4% 0.9926 May 2020 44.0% 57.8% 8.8% 0.9904 June 2020 44.2% 59.4% 8.2% 0.9957 July 2020 43.4% 60.9% 8.6% 1.0065 August 2020 43.7% 59.8% 8.6% 1.0076 September 2020 44.2% 60.8% 8.9% 1.0064 October 2020 43.0% 63.0% 7.9% 1.0134 Home Health Revenue Factors The first 30-day period in an episode is referred to as P1 or Period 1. All other subsequent 30-day periods are referred to as P2. P1 is considered an early episode and receives a higher payment than a P2. Q1 2020 Q2 2020 Q3 2020 Home Health $2,797 $2,771 $2,824 % change compared to prior year -1.9% -2.5% -1.4% % change sequentially -0.9% 1.9% Revenue per completed Medicare episode

Three months ended September 30, Nine months ended September 30, 2020 Adjusted Hospice services % of rev 2019 Adjusted Hospice services % of rev   2020 Adjusted Hospice services % of rev 2019 Adjusted Hospice services % of rev Net service revenue $59,801   $62,028     $181,387   $168,821   Cost of service revenue 36,646 61.3% 35,497 57.2%   109,923 60.6% 103,191 61.1% Gross margin 23,155 38.7% 26,531 42.8%   71,464 39.4% 65,630 38.9% General and administrative expenses 15,867 26.5% 15,081 24.3%   47,418 26.1% 43,380 25.7% Operating income $7,288 12.2% $11,450 18.5% $24,046 13.3% $22,250 13.2% Depreciation 509   455   1,545   1,311   Noncontrolling interests (1,301)   (1,213)     (3,452)   (2,712)   Earnings before interest, tax and depreciation (EBITDA less NCI) $6,496   $10,692     $22,139   $20,849   EBITDA less NCI as a percentage of revenue 10.9%   17.2%     12.2%   12.3%   Hospice adjusted EBITDA margin was 10.9% in the third quarter of 2020 which included a $2.2 million decrease in revenue from the write-off of accounts receivables associated with certain acquired hospice locations. Normalized adjusted EBITDA margin for the third quarter of 2020 is 14.0%. Hospice adjusted EBITDA margin was 17.2% in the third quarter of 2019 which included a $3.0 million improvement in the implicit price concession that was a result of better overall cash collections. Normalized adjusted EBITDA margin for the third quarter of 2019 was 13.0%. Revenue from sequestration suspension in the third quarter of 2020 was $1.2 million. Hospice Segment Adjusted Segment Results – 2020 vs 2019

Three months ended September 30, Nine months ended September 30, 2020 Adjusted HCBS services % of rev 2019 Adjusted HCBS services % of rev   2020 Adjusted HCBS services % of rev 2019 Adjusted HCBS services % of rev Net service revenue $48,387   $53,411     $144,526   $157,610   Cost of service revenue 36,647 75.7% 39,366 73.7%   111,486 77.1% 118,532 75.2% Gross margin 11,740 24.3% 14,045 26.3%   33,040 22.9% 39,078 24.8% General and administrative expenses 10,079 20.8% 10,720 20.1%   31,622 21.9% 32,009 20.3% Operating income $1,661 3.4% $3,325 6.2% $1,418 1.0% $7,069 4.5% Depreciation 418   338   1,217   966   Noncontrolling interests (25)   180     275   757   Earnings before interest, tax and depreciation (EBITDA less NCI) $2,054   $3,843     $2,910   $8,792   EBITDA less NCI as a percentage of revenue 4.2%   7.2%     2.0%   5.6%   Home and Community-Based Services Adjusted EBITDA margin declined 300 basis points in the third quarter of 2020 compared to the same period in 2019. The decline was due to a reduction in billable hours due to the COVID-19 pandemic. Home and Community-Based Services Adjusted EBITDA margin improved 130 basis points sequentially from 2.9% in the second quarter of 2020 to 4.2% in the third quarter of 2020. Home and Community-Based Services billable hours increased 1.1% sequentially over the second quarter of 2020. Home and Community Based Services Segment Adjusted Segment Results – 2020 vs 2019

Facility-Based Services Segment Adjusted Segment Results – 2020 vs 2019 Three months ended September 30, Nine months ended September 30, 2020 Adjusted Facility-based services % of rev 2019 Adjusted Facility-based services % of rev   2020 Adjusted Facility-based services % of rev 2019 Adjusted Facility-based services % of rev Net service revenue $33,344   $28,715     $96,664   $84,391   Cost of service revenue 21,868 65.6% 18,508 64.5%   62,853 65.0% 53,654 63.6% Gross margin 11,476 34.4% 10,207 35.5%   33,811 35.0% 30,737 36.4% General and administrative expenses 10,980 32.9% 9,498 33.1%   30,526 31.6% 27,771 32.9% Operating income $496 1.5% $709 2.5% $3,285 3.4% $2,966 3.5% Depreciation 945   785   2,810   2,310   Noncontrolling interests (230)   67     (1,228)   (779)   Earnings before interest, tax and depreciation (EBITDA less NCI) $1,211   $1,561     $4,867   $4,497   EBITDA less NCI as a percentage of revenue 3.6%   5.4%     5.0%   5.3%   Facility-Based Adjusted EBITDA margin declined 180 basis points in the third quarter of 2020 compared to the same period in 2019 due to higher cost of service as a percent of revenue caused by an increase in contract labor and higher wages during COVID-19 pandemic. Normalized EBITDA margin for the third quarter excluding higher contract labor and wages was 8.8%. Revenue from sequestration suspension in the third quarter of 2020 was $204,000. Revenue from the LTAC qualifying payment replacing site-neutral payment during the Public Health Emergency was $6.4 million in the third quarter of 2020.

Healthcare Innovations Segment Adjusted Segment Results – 2020 vs 2019 Three months ended September 30, Nine months ended September 30, 2020 Adjusted HCI services % of rev 2019 Adjusted HCI services % of rev   2020 Adjusted HCI services % of rev 2019 Adjusted HCI services % of rev Net service revenue $15,702   $8,746     $27,155   $24,217   Cost of service revenue 3,666 23.3% 3,333 38.1%   11,272 41.5% 10,108 41.7% Gross margin 12,036 76.7% 5,413 61.9%   15,883 58.5% 14,109 58.3% General and administrative expenses 3,573 22.8% 2,986 34.1%   9,683 35.7% 11,927 49.3% Operating income $8,463 53.9% $2,427 27.7% $6,200 22.8% $2,182 9.0% Depreciation 302   277   897   856   Noncontrolling interests 7   9     23   22   Earnings before interest, tax and depreciation (EBITDA less NCI) $8,772   $2,713     $7,120   $3,060   EBITDA less NCI as a percentage of revenue 55.9%   31.0%     26.2%   12.6%   The increase in revenue in the third quarter of 2020 as compared to the third quarter in 2019 is due to the receipt of a higher Medicare Shared Savings Payment (MSSP) of $9.6 million as compared to $2.9 million in the third quarter of 2019.

Increased FY 2020 Guidance Original FY 2020 Guidance issued on February 27, 2020 Reinstated FY 2020 Guidance issued on August 5, 2020 Updated FY 2020 Guidance Revenue $2.13 billion to $2.18 billion $2.0 billion to $2.05 billion $2.06 billion to $2.07 billion EPS $4.60 to $4.80 $4.60 to $4.80 $4.90 to $5.00 EBITDA $230 million to $240 million $220 million to $230 million $232 million to $237 million

Acquisition and Joint Ventures Accelerate Again in Second Half of 2020 Acquisition/Joint Venture Partner State Date Closed Locations Annual Revenue DFW Home Health Texas Health Resources/Methodist Health System Texas 1/1/2020 1 $2,400,000 LifePoint Health LifePoint Health Arkansas 1/1/2020 2 $5,400,000 Southeast Louisiana HomeCare Ochsner Health System Louisiana 1/1/2020 5 $16,000,000 Mederi Caretenders/Mederi Private Care Orlando Health System Florida 8/1/2020 6 $3,500,000 University Health Care System University Health Care System Georgia/South Carolina 10/1/2020 10 $8,300,000 Santa Rita Hospice N/A Colorado 10/1/2020 1 $550,000 CHRISTUS Health CHRISTUS Health Texas 11/1/2020 1 $1,600,000 Total acquired or announced revenue in 2020 $37,750,000

Industry-Leading Quality and Patient Satisfaction 85% of LHC Group same-store providers have CMS 4 stars or greater for quality Quality October 2020 LHC Group excluding 2019 acquisitions 4.27 LHC Group with 2019 acquisitions 4.23 National average 3.25 Patient Satisfaction October 2020 LHC Group excluding 2019 acquisitions 4.42 LHC Group with 2019 acquisitions 4.41 National average 3.98 100% of LHC Group home health and hospice agencies are Joint Commission accredited or are in the accreditation process within 12 to 18 months after acquisition. Approximately 15% of all Medicare certified home health agencies nationwide are Joint Commission accreditation. 90% of LHC Group same-store providers have CMS 4 stars or greater for patient satisfaction

Debt and Liquidity Metrics Outstanding Debt (amounts in thousands) As of Sep. 30, 2020 Total Debt – Balance Sheet $20,000 Less: Cash $253,764 Net Debt NA Net debt to estimated TTM adjusted EBITDA ratio NA Credit Facility (amounts in thousands) As of Sep. 30, 2020 Revolver Size $500,000 Less: Outstanding Revolver $20,000 Less: Medicare Advanced Payments and Provider Relief Funds $411,200 Less: Letters of Credit $24,800 Available Liquidity $44,000 Plus: Cash $253,764 Plus: Accordion $200,000 Total Liquidity $497,764 Cash Flow (amounts in thousands) As of Sep. 30, 2020 Free Cash Flow (3 Months Ended) $9,578 + Cash adjustments net of tax to 2020 EBITDA 36,757 = Adjusted Free Cash Flow (3 Months Ended) $46,335 DSO’s 54 days

Focus for Remainder of 2020 Continue the successful execution of our PDGM clinical pathway and efficiency plan. Maintain disciplined capital allocation with new joint ventures and other M&A activity. Accelerate plans for unlocking untapped potential of co-location strategy. Maximize value of Healthcare Innovations business. Maintain proactive posture to COVID-19 pandemic response. Continue to lead the industry in quality and patient satisfaction scores. Capture market share gains and incremental contributions from recent joint ventures and other acquisitions. Capture opportunistic share in each market from anticipated consolidation caused by PDGM and RAP elimination. Continue our focus as an industry leader in key areas around employee recruitment and retention including vacancy rate and voluntary turnover. Prioritize the safety and protection of our employees, patients and communities we serve.

Non-GAAP Reconciliations (Amounts in thousands, unaudited) RECONCILIATION OF ADJUSTED NET INCOME ATTRIBUTABLE TO LHC GROUP Three Months Ended Sep. 30, Three Months Ended Sep. 30, Nine Months Ended Sep. 30, Nine Months Ended Sep. 30, 2020 2019 2020 2019 Net income attributable to LHC Group, Inc.’s common stockholders $14,500 $30,067 $81,216 $73,923 Add (net of tax):         Acquisition and de novo expenses (1) 1,829 8,482 3,345 20,463 Closures/relocations/consolidations (2) - 941 866 4,722 COVID-19 impact: PPE, supplies and other expenses (3) 7,689 - 29,967 - CARES Act tax benefit (4) - - (2,210) - Provider Relief Fund (PRF) (5) 32,882 - NCI Associated with PRF (6) (5,643) - Provider moratorium impairment (7) - - - 4,332 Adjusted net income attributable to LHC Group, Inc.’s common stockholders $51,257 $39,490 $113,184 $103,440 Footnotes are on page 32 RECONCILIATION OF ADJUSTED NET INCOME ATTRIBUTABLE TO LHC GROUP PER DILUTED SHARE Three Months Ended Sep. 30, Three Months Ended Sep. 30, Nine Months Ended Sep. 30, Nine Months Ended Sep. 30, 2020 2019 2020 2019 Net income attributable to LHC Group, Inc.’s common stockholders per diluted share $0.46 $0.96 $2.59 $2.37 Add (net of tax):         Acquisition and de novo expenses (1) 0.05 0.27 0.11 0.66 Closures/relocations/consolidations (2) - 0.03 0.03 0.15 COVID-19 impact: PPE, supplies and other expenses (3) 0.25 - 0.95 - CARES Act tax benefit (4) - - (0.07) - Provider Relief Fund (PRF) (5) 1.05 - - - NCI Associated with PRF (6) (0.18) - - - Provider moratorium impairment (7) - - - 0.14 Adjusted net income attributable to LHC Group, Inc.’s common stockholders $1.63 $1.26 $3.61 $3.32

Footnotes: Expenses and other costs associated with recently announced or completed acquisitions and de novos ($2.5 million and $4.6 million pre-tax in the third quarter and first nine months of 2020, respectively). Loss on the sale of an asset and other expenses associated with a closure on consolidation (none in the third quarter and $1.2 million pre-tax in the first nine months of 2020). COVID-19 related expenses for purchases of personal protective equipment (“PPE”), supplies and employee benefit expenses including bonuses and increased wages, wage supplements and PTO replenishments for front line caregivers ($10.5 million and $40.6 million pre-tax in the third quarter and first nine months of 2020, respectively). Tax benefit related to new legislation in the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which lifts certain tax deduction limitations and eliminates 80% of taxable income limitations for Net Operating Losses (“NOL”), which we are now able to fully utilize NOLs associated with Almost Family prior to the merger. Based on improved current and projected future results, the Company intends to return the entire $93.3 million in funds it has received from the Provider Relief Fund (PRF) under the CARES Act and for the consolidated results for the third quarter of 2020 has reversed the $44.4 million in government stimulus income recognized during the second of 2020 related to general distribution funds received from the PRF ($44.4 million pre-tax). Non-controlling interest distributed to our Joint Venture partners in association with the government stimulus income recognized during the second quarter of 2020 ($7.6 million pre-tax) was reversed in the three months ended September 30, 2020 based on the reversal of the government stimulus income recognized during the second quarter of 2020. During the first quarter of 2019, the Company recorded $6.0 million of moratoria impairment as a result of the Centers for Medicare and Medicaid Services (“CMS”) action to remove all federal moratoria with regard to Medicare provider enrollment. In assigning fair value acquired in acquisitions as required by ASC 805, Business Combinations, the Company had assigned fair value to Certificates of need or license moratoria, as applicable, in certain states.   Three Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, Nine Months Ended September 30,   2020 2019 2020 2019 Net income $14,500 $30,067 $81,216 $73,923 Add:         Income tax expense 4,595 9,508 23,181 22,665 Interest expense, net 431 2,596 4,040 8,533 Depreciation and amortization 5,217 4,412 15,601 12,812 Adjustment items (*) 49,775 13,033 46,339 40,841 Adjusted EBITDA $74,518 $59,616 $170,377 $158,774           (*) Adjustment items (pre-tax):         Acquisition and de novo expenses (1) $2,492 $11,731 $4,556 $28,305 Closures/relocations/consolidations (2) - 1,302 1,174 6,536 COVID-19 expenses (3) 10,474 - 40,609 - Provider Relief Fund (PRF) (5) 44,435 - - - NCI associated with PRF (6) (7,626) - - - Provider moratorium impairment (7) - - - 6,000 Total adjustments $49,775 $13,033 $46,339 $40,841 Non-GAAP Reconciliations (Amounts in thousands, unaudited) Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)